<DOC>
	<DOCNO>NCT00082563</DOCNO>
	<brief_summary>The purpose study determine Azithromycin combination chloroquine superior chloroquine alone eradicate P. falciparum asexual parasitemia asymptomatic , semi-immune adult Western Kenya .</brief_summary>
	<brief_title>Azithromycin Combination With Chloroquine Versus Chloroquine Eradication Asymptomatic Plasmodium Falciparum</brief_title>
	<detailed_description>The trial terminate prematurely 9 November 2004 due inability recruit plan number subject . There safety efficacy concern regard study decision terminate trial .</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Healthy adult : male female Asymptomatic monoinfection P. falciparum parasitemia parasite density 1000 30,000 parasites/Î¼L Age 18 year 60 year Willingness sign ability understand consent form Willingness ability return schedule follow visit Mixed malaria infection Giemsa smear History allergy hypersensitivity chloroquine , Azithromycin macrolides ( e.g . erythromycin , clarithromycin ) Any follow : . ) Antimalarial therapy administer past 4 week , include quinine therapy artemisinin derivative ; b . ) An antibacterial known antimalarial activity ( include , erythromycin , doxycycline , clindamycin , cotrimoxazole ) within one week prior enrollment study Fever , history fever past 48 hour , signs/symptoms malaria ( include acute subacute headache , nausea , vomit ) Inability swallow oral medication Laboratory evidence history significant cardiovascular , liver , hematologic renal functional abnormality Any situation could prevent patient return follow visit Pregnancy breast feed Any concurrent illness may confound result Any condition circumstance opinion Investigator may pose threat study participant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>